Search results for "tumor cells"

showing 10 items of 663 documents

The Potential Role of Medicinal Mushrooms in the Prevention and Treatment of Gynecological Cancers: A Review

2019

A review of scientific information about the potential role of medicinal mushrooms in the prevention and treatment of gynecological cancers, human immunodeficiency virus, and human papillomavirus infections is reported here. The results of in vivo and in vitro experiments on 16 different species of Basidiomycetes and three Ascomycetes, which possess chemopreventive potential and are effective in clinical application in combination with chemotherapy, are also discussed. Medicinal mushroom extracts confirm an evident efficacy on the reduction of tumor cell proliferation and side effects in patients with gynecological tumors who are undergoing chemotherapy treatments. This review, the first on…

0106 biological sciencesanimal structuresVaginal NeoplasmsGenital Neoplasms Femalemedicine.medical_treatmentHuman immunodeficiency virus (HIV)Uterine Cervical NeoplasmsTumor cellsmedicine.disease_cause01 natural sciencesApplied Microbiology and BiotechnologyAntioxidantsMiceMedicinal mushroomAscomycotaIn vivo010608 biotechnologyDrug DiscoverymedicineAnimalsHumansIn patientHuman papillomavirusPapillomaviridaeCell ProliferationPharmacologyChemotherapyBiological ProductsClinical Trials as Topicbusiness.industryBasidiomycotafungiHIVSettore BIO/03 - Botanica Ambientale E ApplicataCancer researchFemalebusinessAgaricalesmedicinal mushrooms gynecological cancers human immunodeficiency virus human papillomavirus Basidiomycetes Ascomycetes
researchProduct

Polyphosphate as a donor of high-energy phosphate for the synthesis of ADP and ATP.

2017

Here, we studied the potential role of inorganic polyphosphate (polyP) as an energy source for ADP and ATP formation in the extracellular space. In SaOS-2 cells, we show that matrix vesicles are released into the extracellular space after incubation with polyP. These vesicles contain both alkaline phosphatase (ALP) and adenylate kinase (AK) activities (mediated by ALPL and AK1 enzymes). Both enzymes translocate to the cell membrane in response to polyP. To distinguish the process(es) of AMP and ADP formation during ALP hydrolysis from the ATP generated via the AK reaction, inhibition studies with the AK inhibitor A(5')P5(5')A were performed. We found that ADP formation in the extracellular …

0301 basic medicineAdenylate kinaseBiologydigestive systemExocytosisCatalysisCell membrane03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAdenosine TriphosphatePolyphosphatesExtracellularmedicineTumor Cells CulturedHumansPhosphorylationchemistry.chemical_classificationATP synthasePolyphosphateAdenylate KinaseCell BiologyAlkaline PhosphataseAdenosine DiphosphateKinetics030104 developmental biologyEnzymemedicine.anatomical_structurechemistryBiochemistry030220 oncology & carcinogenesisbiology.proteinEnergy sourceEnergy MetabolismExtracellular SpaceJournal of cell science
researchProduct

2019

The P-STS human ileal neuroendocrine tumor cells, as a model for gut enterochromaffin cells, are strongly and synergistically activated by histamine plus acetylcholine (ACh), presumably via histamine 4 receptors, and weakly activated by histamine alone. Sensing these signals, enterochromaffin cells could participate in intestinal intolerance or allergic reactions to food constituents associated with elevated histamine levels. In this study we aimed to analyze the underlying molecular mechanisms. Inhibition by mepyramine and mibefradil indicated that histamine alone caused a rise in intracellular calcium concentration ([Ca2+]i) via histamine 1 receptors involving T-type voltage-gated calciu…

0301 basic medicineAgonistCalcium metabolismHepatologyVoltage-dependent calcium channelPhysiologymedicine.drug_classGastroenterologyTumor cellsPharmacologyCalcium in biology03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicinechemistryPhysiology (medical)medicineEnterochromaffin cell030217 neurology & neurosurgeryHistamineAcetylcholinemedicine.drugAmerican Journal of Physiology-Gastrointestinal and Liver Physiology
researchProduct

Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines

2019

T cells are key effectors of anticancer immunity. They are capable of distinguishing tumor cells from normal ones by recognizing major histocompatibility complex–bound cancer-specific peptides. Accumulating evidence suggests that peptides associated with T cell–mediated tumor rejection arise predominantly from somatically mutated proteins and are unique to every patient's tumor. Knowledge of an individual's cancer mutanome (the entirety of cancer mutations) allows harnessing this enormous tumor cell–specific repertoire of highly immunogenic antigens for individualized cancer vaccines. This review outlines the preclinical and clinical state of individualized cancer vaccine development and t…

0301 basic medicineAnticancer immunityT-Lymphocytesmedicine.medical_treatmentTumor cellsCancer VaccinesGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineAntigens NeoplasmNeoplasmsAnimalsHumansMedicineMolecular Targeted TherapyPrecision Medicinebusiness.industryEffectorCancerGeneral MedicineImmunotherapymedicine.diseaseTreatment Outcome030104 developmental biology030220 oncology & carcinogenesisMutationCancer researchImmunotherapybusinessForecastingMajor histocompatibilityAnnual Review of Medicine
researchProduct

DNA demethylation caused By 5-Aza-2'-Deoxycytidine induces mitotic alterations and aneuploidy

2016

Aneuploidy, the unbalanced number of chromosomes in a cell, is considered a prevalent form of genetic instability and is largely acknowledged as a condition implicated in tumorigenesis. Epigenetic alterations like DNA hypomethylation have been correlated with cancer initiation/progression. Furthermore, a growing body of evidence suggests the involvement of epigenome-wide disruption as a cause of global DNA hypomethylation in aneuploidy generation. Here, we report that the DNA hypomethylating drug 5-aza-2′-deoxycytidine (DAC), affects the correct ploidy of nearly diploid HCT-116 human cells by altering the methylation pattern of the chromosomes. Specifically, we show that a DAC-induced reduc…

0301 basic medicineAntimetabolites Antineoplastic5-aza-2'-deoxycytidine (DAC); Aneuploidy; Chromosome methylation pattern; Chromosome Section; DNA demethylation; OncologyBlotting WesternAneuploidyMitosisApoptosisBiologymedicine.disease_causeDecitabineReal-Time Polymerase Chain ReactionChromosome Section03 medical and health scienceschromosome methylation patternChromosome instabilitymedicineTumor Cells CulturedHumansEpigeneticsaneuploidyRNA Messenger5-aza-2′-deoxycytidine (DAC)Cell ProliferationGeneticsChromosome AberrationsPloidiesReverse Transcriptase Polymerase Chain ReactionDNA Methylationmedicine.disease5-aza-2'-deoxycytidine (DAC)Gene Expression Regulation NeoplasticResearch Paper: ChromosomeSettore BIO/18 - Genetica030104 developmental biologyDNA demethylationOncologyMicroscopy FluorescenceDNA methylationColonic NeoplasmsCytogenetic AnalysisCancer researchDNA demethylationAzacitidinePloidyCarcinogenesisDNA hypomethylation
researchProduct

Novel iodoacetamido benzoheterocyclic derivatives with potent antileukemic activity are inhibitors of STAT5 phosphorylation

2016

Signal Transducer and Activator of Transcription 5 (STAT5) protein, a component of the STAT family of signaling proteins, is considered to be an attractive therapeutic target because of its involvement in the progression of acute myeloid leukemia. In an effort to discover potent molecules able to inhibit the phosphorylation-activation of STAT5, twenty-two compounds were synthesized and evaluated on the basis of our knowledge of the activity of 2-(3’,4’,5’-trimethoxybenzoyl)-3-iodoacetamido-6-methoxy benzo[b]furan derivative 1 as a potent STAT5 inhibitor. Most of these molecules, structurally related to compound 1, were characterized by the presence of a common 3’,4’,5’-trimethoxybenzoyl moi…

0301 basic medicineApoptosisAntineoplastic Agentchemistry.chemical_compoundBenzophenone0302 clinical medicinehemic and lymphatic diseasesFuranDrug DiscoverySTAT5 Transcription FactorTumor Cells CulturedThiopheneMoietyPhosphorylationSTAT5Molecular StructurebiologyChemistryBiological activityGeneral MedicineApoptosis; BCR/ABL expressing leukemia; In vitro antiproliferative activity; STAT5 inhibitors; Structure-activity relationship; Drug Discovery3003 Pharmaceutical Science; Organic Chemistry; PharmacologyLeukemia Myeloid Acute030220 oncology & carcinogenesisBCR/ABL expressing leukemiaApoptosis; BCR/ABL expressing leukemia; In vitro antiproliferative activity; STAT5 inhibitors; Structure-activity relationship; Antineoplastic Agents; Apoptosis; Benzofurans; Benzophenones; Cell Proliferation; Dose-Response Relationship Drug; Drug Screening Assays Antitumor; Humans; K562 Cells; Leukemia Myeloid Acute; Molecular Structure; Phosphorylation; STAT5 Transcription Factor; Structure-Activity Relationship; Tumor Cells Cultured; Drug Discovery3003 Pharmaceutical Science; Organic Chemistry; PharmacologyHumanStereochemistryAntineoplastic AgentsArticleNOBenzophenones03 medical and health sciencesK562 CellHumansStructure–activity relationshipBenzofuransCell ProliferationPharmacologyIndole testDose-Response Relationship DrugIn vitro antiproliferative activitySTAT5 inhibitorsDrug Discovery3003 Pharmaceutical ScienceOrganic ChemistryApoptosiSTAT5 inhibitorStructure-activity relationshipIn vitro030104 developmental biologybiology.proteinBenzofuranDrug Screening Assays AntitumorK562 Cells
researchProduct

A headlight on liquid biopsies: a challenging tool for breast cancer management

2016

Breast cancer is the most frequent carcinoma and second most common cause of cancer-related mortality in postmenopausal women. The acquisition of somatic mutations represents the main mechanism through which cancer cells overcome physiological cellular signaling pathways (e.g., PI3K/Akt/mTOR, PTEN, TP53). To date, diagnosis and metastasis monitoring is mainly carried out through tissue biopsy and/or re-biopsy, a very invasive procedure limited only to certain locations and not always feasible in clinical practice. In order to improve disease monitoring over time and to avoid painful procedure such as tissue biopsy, liquid biopsy may represent a new precious tool. Indeed, it represents a bas…

0301 basic medicineCA15-3OncologyCancer Researchmedicine.medical_specialtyPathologyBiopsyBreast NeoplasmsMetastasis03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancerCirculating tumor cellInternal medicineBiopsyBiomarkers TumormedicineCarcinomaHumansPTENNeoplasm MetastasisLiquid biopsyBreast cancer; Circulating tumor cells; Circulating tumor DNA; CTCs; ctDNA; Liquid biopsy; Cancer ResearchCirculating tumor DNALiquid biopsybiologymedicine.diagnostic_testbusiness.industryCirculating tumor cellctDNADNA NeoplasmGeneral MedicineNeoplastic Cells Circulatingmedicine.diseaseCTC030104 developmental biology030220 oncology & carcinogenesisbiology.proteinFemalebusinessTumor Biology
researchProduct

Extracellular Vesicles Shed by Melanoma Cells Contain a Modified Form of H1.0 Linker Histone and H1.0 mRNA-binding Proteins

2016

Extracellular vesicles (EVs) are shed in the extracellular environment by both prokaryotes and eukaryotes. Although produced from both normal and cancer cells, malignant cells release a much higher amount of EVs, which also contain tumor-specific proteins and RNAs. We previously found that G26/24 oligodendroglioma cells shed EVs that contain the pro-apoptotic factors FasL and TRAIL1-2. Interestingly, G26/24 release, via EVs, extracellular matrix remodelling proteases3, and H1° histone protein4, and mRNA. To shed further light on the role of EVs in discarding proteins and mRNAs otherwise able to counteract proliferative signals, we studied a melanoma cell line (A375). We found that also thes…

0301 basic medicineCancer ResearchCellular differentiationBlotting WesternFluorescent Antibody TechniqueMYEF2ApoptosisRNA-binding proteinexosomesmembrane vesiclesReal-Time Polymerase Chain ReactionChromatography AffinityHistones03 medical and health sciencesH1.0 linker histone; RNA-binding proteins (RBPs); extracellular vesicles (EVs) membrane vesicles (MVs); exosomes; MYEF2Settore BIO/10 - BiochimicaTumor Cells CulturedHumansexosomeSecretionRNA MessengerSettore BIO/06 - Anatomia Comparata E Citologiamelanoma cell line (A375) myelin expression factor-2 (MYEF2)MelanomaTranscription factorCell ProliferationH1.0 linker histonebiologyReverse Transcriptase Polymerase Chain ReactionEXTRACELLULAR VESICLESRNA-Binding ProteinsRNACell DifferentiationArticlesCell biologyBlotCell Transformation Neoplastic030104 developmental biologyHistoneOncologySpectrometry Mass Matrix-Assisted Laser Desorption-IonizationCancer cellbiology.proteinRNA-binding proteins (RBPs)extracellular vesicles (EVs) membrane vesicles (MVs)
researchProduct

Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs

2020

Abstract Myeloid-derived suppressor cells (MDSC) include immature monocytic (M-MDSC) and granulocytic (PMN-MDSC) cells that share the ability to suppress adaptive immunity and to hinder the effectiveness of anticancer treatments. Of note, in response to IFNγ, M-MDSCs release the tumor-promoting and immunosuppressive molecule nitric oxide (NO), whereas macrophages largely express antitumor properties. Investigating these opposing activities, we found that tumor-derived prostaglandin E2 (PGE2) induces nuclear accumulation of p50 NF-κB in M-MDSCs, diverting their response to IFNγ toward NO-mediated immunosuppression and reducing TNFα expression. At the genome level, p50 NF-κB promoted binding …

0301 basic medicineCancer ResearchCellular differentiationProstaglandin E2 receptormedicine.medical_treatmentMelanoma ExperimentalApoptosisSettore MED/08 - Anatomia PatologicaNitric OxideDinoprostoneMonocytesInterferon-gammaMice03 medical and health sciences0302 clinical medicineImmune systemOxytocicsImmune ToleranceTumor Cells CulturedmedicineAnimalsHumansProstaglandin E2Cell ProliferationChemistryMyeloid-Derived Suppressor CellsNF-kappa B p50 SubunitCell DifferentiationImmunotherapyAcquired immune systemPancreatic Neoplasms030104 developmental biologyOncologyp50 NF-κB differentiation of monocytic MDSC.030220 oncology & carcinogenesisMyeloid-derived Suppressor CellCancer researchTumor necrosis factor alphaColorectal Neoplasmsmedicine.drugCancer Research
researchProduct

Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy

2018

MET, a master gene sustaining "invasive growth," is a relevant target for cancer precision therapy. In the vast majority of tumors, wild-type MET behaves as a "stress-response" gene and relies on the ligand (HGF) to sustain cell "scattering," invasive growth and apoptosis protection (oncogene "expedience"). In this context, concomitant targeting of MET and HGF could be crucial to reach effective inhibition. To test this hypothesis, we combined an anti-MET antibody (MvDN30) inducing "shedding" (i.e., removal of MET from the cell surface), with a "decoy" (i.e., the soluble extracellular domain of the MET receptor) endowed with HGF-sequestering ability. To avoid antibody/decoy interaction-and …

0301 basic medicineCancer ResearchLung NeoplasmsCellContext (language use)ApoptosisMice SCIDLigands03 medical and health sciencesMice0302 clinical medicineMice Inbred NODanti-HGF therapy; antibodies; decoy; MET oncogene; MET target therapyMET oncogeneExtracellularmedicineTumor Cells CulturedantibodiesAnimalsHumansdecoyCell ProliferationOncogenebiologyMET target therapyChemistryAntibodies MonoclonalProto-Oncogene Proteins c-metXenograft Model Antitumor AssaysIn vitro030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer cellColonic NeoplasmsCancer researchbiology.proteinanti-HGF therapyFemaleAntibodyDecoyGlioblastoma
researchProduct